CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSPECTIVE ANALYSES OF NEW POTENTIAL MOLECULAR PREDICTORS OF OUTCOME

Primary objectives: to prospectively verify if the activity of cetuximab plus irinotecan combination treatment in metastatic colorectal cancer patients could be significantly improved selecting those bearing KRAS wild-type tumors and with EGFR intron 1 CA tandem repeats S/S or S/L germline genetic variants Primary endpoints: The primary study endpoint is response rate